JANSEN RESEARCH & DEVELOPMENT (CNTO136ARA3003)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered  Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy.